Anterix vs Surgepays
Surgepays is the larger business, with $57.0m of revenue in fiscal 2025 against $6.5m for Anterix (8.8 times as much). Anterix grew faster (7.8% against -6.4%). Anterix kept more of each dollar of sales as profit: a net margin of 1394.2% against -63.3%.
| Latest fiscal year | AnterixATEX, 2026 | SurgepaysSURG, 2025 |
|---|---|---|
| Revenue | $6.5m | $57.0m |
| Revenue growth | 7.8% | -6.4% |
| Net income | $90.6m | −$36.1m |
| Operating margin | 1444.9% | — |
| Net margin | 1394.2% | -63.3% |
| Return on equity | 43.3% | — |
| Free cash flow | $5.5m | −$21.3m |
| Cash | $98.5m | $1.7m |
| Total debt | $0 | $22.1m |
| Debt to equity | 0.0% | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | $990,000 | — |
| Employees | 64 | — |
| Market value | $1.64bn | $4.1m |
| Price vs our value range | — | — |
| Moat score | 12 (Weak) | 18 (Weak) |
| Insider trades, 12 months | 2 buys, 48 sales | 5 buys, 0 sales |